Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder

Authors Renzo Colombo, Richard Naspro, Piera Bellinzoni, Fabio Fabbri, Giorgio Guazzoni, et al

Published 15 January 2008 Volume 2007:3(6) Pages 1003—1007

Renzo Colombo1, Richard Naspro2, Piera Bellinzoni2, Fabio Fabbri2, Giorgio Guazzoni2, Vincenzo Scattoni1, Andrea Losa2, Patrizio Rigatti1

1Department of Urology, University Vita-Salute San Raffaele, Scientific Institute H. San Raffaele, Milan, Italy; 2Department of Urology, San Raffaele Turro, Milan, Italy

Introduction: A prospective study to evaluate the reliability of cystoscopy was performed with fluorescence (photodynamic diagnosis, PDD) compared with standard white light (WL) cystoscopy in patients with solitary carcinoma in situ (CIS), undergoing BCG treatment.

Materials and methods: Between February 2004 and March 2006, 49 patients suffering from CIS were enrolled in the study. Patients age was 68.5 ± 13.5 years (mean ± SD) and all presented CIS alone at inclusion. All suspicious areas were biopsied either under white light or blue light. Urine cytology was peformed on each patient before endoscopy.

Results: Out of 49 patients enrolled, 15 (30.6%) presented with positive urinary cytology. Out of 18 patients positive to CIS at biopsy, 14 (77.7%) could be diagnosed exclusively by means of PDD cystoscopy and transurethral bladder resection and 4 (22.3%) during both standard and PDD cystoscopy. No additional CIS could be diagnosed by standard WL cystoscopy alone. The overall false positive rate for PDD accounted for 33.3% compared with 7.1% for WL cytoscopy. A statistical correlation was documented between the number of CIS findings and PDD (r = 0.6976, p = 0.0002) while WL cystoscopy (r = 0.1870, p = 0.3816) and urinary cytology (r = 0.4965, p = 0.0136) correlated only weakly with CIS. The overall side effects related to the drugs were negligible overall.

Conclusions: These data show that PDD cystoscopy is more reliable than WL cytoscopy for the follow-up of CIS patients during BCG treatment. Long-term data and multicenter, prospective data are needed to assess the true impact on tumor recurrence and progression.
Keywords: bladder cancer, fluorescence, carcinoma in situ, endoscopy

Download Article [PDF] 

Readers of this article also read:

Erratum

Erhardt L, Moller R, Puig JC. 2007

Vascular Health and Risk Management 2008, 4:741-741

Published Date: 6 June 2008

Review of photodynamic therapy in actinic keratosis and basal cell carcinoma

Marica B Ericson, Ann-Marie Wennberg, Olle Larkö

Therapeutics and Clinical Risk Management 2008, 4:1-9

Published Date: 8 February 2008

Recombinant human epoetin beta in the treatment of renal anemia

Francesco Locatelli, Pietro Pozzoni, Lucia Del Vecchio

Therapeutics and Clinical Risk Management 2007, 3:433-439

Published Date: 15 July 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007

Infliximab in the treatment of Crohn’s disease

Gilberto Poggioli, Silvio Laureti, Massimo Campieri, Filippo Pierangeli, Paolo Gionchetti, et al

Therapeutics and Clinical Risk Management 2007, 3:301-308

Published Date: 15 May 2007